---
title: "688505.SH (688505.SH) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/688505.SH/news.md"
symbol: "688505.SH"
name: "688505.SH"
parent: "https://longbridge.com/en/quote/688505.SH.md"
datetime: "2026-05-21T01:00:57.117Z"
locales:
  - [en](https://longbridge.com/en/quote/688505.SH/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688505.SH/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688505.SH/news.md)
---

# 688505.SH (688505.SH) — Related News

### [Fudan-Zhangjiang: Qin Lei resigns as Deputy General Manager](https://longbridge.com/en/news/286255157.md)
*2026-05-13T11:51:05.000Z*
> Fudan-Zhangjiang announced that Vice General Manager Qin Lei has resigned and will not hold any other positions after re

### [The concept of generic drugs fluctuates and rises, Huasun hits the limit up](https://longbridge.com/en/news/284679324.md)
*2026-04-30T02:25:14.000Z*
> The concept of generic drugs is fluctuating upwards, with Huasun hitting the daily limit, NUCIEN PHARMA rising over 16%,

### ["Performance" Fudan-Zhangjiang's net profit in the first quarter was 7.71 million RMB, an increase of 189.4%](https://longbridge.com/en/news/284586987.md)
*2026-04-29T13:43:35.000Z*
> Fudan-Zhangjiang announced its first-quarter report, with operating revenue of 149 million RMB (same below), a year-on-y

### [Fudan-Zhangjiang released its first-quarter performance, with a net profit attributable to the parent company of approximately 7.7116 million yuan, a year-on-year increase of 189.36%](https://longbridge.com/en/news/284549670.md)
*2026-04-29T10:45:05.000Z*
> Fudan-Zhangjiang released its Q1 2026 performance, with operating revenue of approximately 149 million yuan, a year-on-y

### [Fudan-Zhangjiang: The first subject has been enrolled in the Phase I clinical trial of FZ-P001 sodium for the visualization of malignant lesions during ovarian cancer surgery](https://longbridge.com/en/news/282166794.md)
*2026-04-09T09:19:00.000Z*
> According to a report from Economic Information Agency on the 9th, Fudan-Zhangjiang (Shanghai: 688505) announced that th

### [The first subject has been enrolled in the Phase I clinical trial of FZ-P001 sodium, developed by Fudan-Zhangjiang, for the visualization of malignant lesions during ovarian cancer surgery](https://longbridge.com/en/news/282162419.md)
*2026-04-09T08:55:03.000Z*
> Fudan-Zhangjiang announced that the Phase I clinical trial of its injectable FZ-P001 sodium for the visualization of mal

### [Fudan-Zhangjiang subscribed to a structured deposit product from SPD Bank for 210 million yuan](https://longbridge.com/en/news/281874627.md)
*2026-04-07T11:39:03.000Z*
> Fudan-Zhangjiang signed an agreement with SPD Bank to subscribe to a structured deposit product with a total amount of 2

### [Fudan Zhangjiang Invests RMB210 Million in Low-Risk SPD Bank Structured Deposit](https://longbridge.com/en/news/281907995.md)
*2026-04-07T11:18:13.000Z*
> Shanghai Fudan Zhangjiang Bio Pharmaceutical Co. has invested RMB210 million in a low-risk structured deposit with SPD B